Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
523 studies found for:    multiple myeloma | Open Studies | multiple myeloma
Show Display Options
Rank Status Study
1 Available Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma
Conditions: Multiple Myeloma in Relapse;   Multiple Myeloma
Interventions: Drug: Ulocuplumab;   Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
2 Recruiting Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
Condition: Multiple Myeloma
Interventions: Procedure: Tumor Cell Collection;   Procedure: Autologous Stem Cell Transplant;   Drug: Melphalan;   Procedure: Leukapheresis;   Biological: Myeloma vaccine;   Drug: GM-CSF;   Drug: Lenalidomide
3 Recruiting Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Conditions: Plasma Cell Dyscrasias;   Monoclonal Gammopathy of Undetermined Significance;   AL Amyloidosis;   Multiple Myeloma
Intervention: Procedure: tissue banking
4 Recruiting A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)
Condition: Multiple Myeloma
Interventions: Drug: Revlimid;   Drug: Velcade;   Drug: dexamethasone;   Drug: Farydak
5 Recruiting Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Dexamethasone
6 Recruiting Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma;   Infection
Interventions: Drug: Standard myeloma treatment;   Drug: Clarithromycin;   Drug: Sulfamethoxazole/trimethoprim;   Drug: Observation
7 Recruiting Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma in Relapse;   Multiple Myeloma, Refractory
Interventions: Drug: Pomalidomide;   Drug: Cyclophosphamide;   Drug: Dexamethasone
8 Recruiting Trial of Combination of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Conditions: Smoldering Myeloma;   Smoldering Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Lenalidomide;   Drug: Dexamethasone
9 Recruiting Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Relapsed or Refractory Multiple Myeloma (BMT-03)
Conditions: Multiple Myeloma, Relapsed;   Multiple Myeloma, Refractory to Standard Treatment
Interventions: Radiation: Total Marrow Irradiation;   Drug: Melphalan;   Drug: Filgrastim (G-CSF)
10 Recruiting Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: blood samples;   Biological: Bone marow samples
11 Unknown  VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)
Condition: Multiple Myeloma
Intervention: Drug: bortezomib
12 Unknown  Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: thalomid;   Drug: lenalidomide;   Drug: clarithromycin;   Drug: dexamethasone
13 Recruiting Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ibrutinib;   Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: Placebo
14 Recruiting Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Conditions: Multiple Myeloma;   Waldenstrom's Macroglobulinemia;   Smoldering Multiple Myeloma;   Lymphoblastic Lymphoma
Intervention:
15 Recruiting Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: fludarabine phosphate;   Other: melphalan;   Radiation: total marrow irradiation;   Drug: tacrolimus;   Drug: sirolimus;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
16 Recruiting A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.
Condition: Multiple Myeloma
Intervention: Drug: IMNOVID
17 Recruiting A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma in Relapse
Interventions: Drug: Panobinostat;   Drug: Dexamethasone;   Drug: Lenalidomide;   Drug: Bortezomib
18 Recruiting Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: lenalidomide;   Drug: dexamethasone;   Drug: carfilzomib;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
19 Unknown  Study of DNA Samples From Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Intervention: Genetic: polymorphism analysis
20 Unknown  89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: 89Zr-bevacizumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years